Moderna (MRNA) shares surged 14% to $68 in Friday afternoon trading, reaching a new 52-week high of $69.29. The rally significantly outpaced peers Merck (MRK), which rose 2%, and Pfizer (PFE), which gained 2%. Analysts attribute the move to momentum from a recent FDA advisory...
Moderna Inc. (NASDAQ: MRNA) shares surged approximately 6.21% on Tuesday, June 23, 2026, driven by a unanimous FDA advisory committee vote favoring its mRNA-1010/mFLUSIVA seasonal flu vaccine for adults aged 50 and older. The stock climbed from roughly $47 to $63 over the preceding month,...
Moderna, Inc. (MRNA) is a biotechnology company that transitioned from a platform-stage entity to a commercial vaccine producer following the global success of its COVID-19 vaccine. The company leverages messenger RNA technology to direct cells in producing proteins for immune responses or addressing disease biology...
Moderna Inc.'s mRNA-based influenza vaccine has received a recommendation for approval from an external advisory committee of the US Food and Drug Administration (FDA). This development marks a significant positive milestone for the biotechnology company, which has faced scrutiny regarding this specific product line at...
Moderna (MRNA) stock has surged for a fifth consecutive day following the publication of FDA briefing documents indicating that immunogenicity data from its mFlusiva flu shot may support effectiveness in adults aged 65 and older. This represents a significant regulatory shift, as the FDA had...
Moderna (MRNA) shares surged 9% today, extending a remarkable 94% gain year-to-date to trade near $57. This performance significantly outpaces peers Pfizer (PFE), which is up 4%, and Novavax (NVAX), which is up 41%. The rally is driven by corporate restructuring rather than new clinical...
Moderna has launched Moderna Direct, a new direct-to-healthcare ordering platform powered by FFF Enterprises' proprietary BioSupply® ecommerce technology. This strategic partnership allows Moderna to bypass traditional distribution channels and offer its customers a customized, branded experience for accessing its product portfolio. The launch represents a...
On May 21, 2026, Flagship Pioneering, LLC executed a matched exercise-and-sell transaction involving Moderna (MRNA) shares. The entity exercised stock options to acquire 9,263 shares at an exercise price of $19.15 per share. Immediately following the acquisition, Flagship Pioneering sold the exact same quantity of...
The FDA scheduled a public advisory committee meeting for June 18 to review Moderna's experimental mRNA flu vaccine, Mflusiva, examining its safety and effectiveness before a potential approval later in August. This meeting follows an initial rejection of the application in February by former FDA...
The article argues that while Moderna (MRNA) recently surged 63% year-to-date following a Q1 revenue triple, its long-term fundamentals remain weak. Full-year 2025 revenue collapsed to $1.94 billion, a roughly 40% drop, with management projecting only up to 10% growth for 2026 off this depressed...
Moderna (NASDAQ:MRNA) was ranked number one on TIME's 2026 list of the World's Most Impactful Companies, a distinction based on the Upright Project's Net Impact Model which evaluates net-positive contributions across Society, Knowledge, Health, and Environment. The recognition highlights Moderna's status as a pioneer in...
Moderna faces significant commercial headwinds as mRNA vaccines struggle in post-pandemic markets, prompting a strong sell recommendation based on underperformance against traditional competitors. RSV and flu mRNA candidates are criticized for lower durability, higher side effects, and weak market uptake, resulting in program cuts and...
Moderna (MRNA) shares recently surged, gaining up to 22% over two days, driven by investor speculation regarding a hantavirus outbreak linked to an Atlantic cruise ship. The incident resulted in three fatalities and sparked international headlines, triggering market memory from the 2020 pandemic era despite...
Simply Wall St analyzes Moderna (MRNA), noting a recent surge with a 51.4% year-to-date return and a current price of $46.71. The article questions whether the market has overvalued the stock, citing a DCF model that projects significant future cash outflows until 2030, resulting in...
Moderna (MRNA) shares rose 4.6% following a post-earnings repricing driven by stronger international vaccine deliveries and reiterated growth frameworks for 2026. The company reported first-quarter 2026 revenue of $389 million, with approximately 80% derived from international markets under long-term partnership agreements. Management highlighted a plan...
Moderna (MRNA) is returning to investor focus following its Q1 2026 earnings report, which revealed significant revenue growth driven by vaccine approvals but offset by substantial litigation costs. The company reported quarterly revenue of US$389 million, a sharp increase from US$108 million in the same...
Moderna Inc (MRNA) reported Q1 2026 revenue of $400 million, representing a significant $300 million year-over-year increase, with costs of sales rising to $955 million primarily due to an $878 million litigation settlement related to Arbutus and Genevant. On a GAAP basis, the company recorded...
Moderna Inc. is preparing to report its first-quarter earnings ahead of a Friday market open, with investors anticipating a significant revenue decline as the company transitions away from its pandemic-era dominance. Analysts project a loss of $2.02 per share on expected revenue of $251.76 million,...
The pharmaceutical industry is undergoing a strategic shift from competing on individual assets to building scalable RNA platforms that integrate biology, data science, manufacturing, and clinical development into an adaptive engine. This transition moves competition away from molecule-by-molecule dynamics toward systems that generate therapies efficiently....
Moderna (MRNA) is set to report its first-quarter earnings on Friday, May 1, before the market opens, as investors closely monitor the company’s performance following a prolonged post-pandemic downturn. The primary focus will be on whether the company can demonstrate signs of revenue stabilization after...
